Effect of liver cirrhosis on phenylalanine and tyrosine metabolism

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 13, Issue 1, 2010, Pages 81-86

  Tessari, Paolo ^a   Vettore, Monica ^a   Millioni, Renato ^a   Puricelli, Lucia ^a   Orlando, Rocco ^b  

^a Chair of Metabolism ^*  (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Compensated liver cirrhosis; Mixed meal; Stable isotopes; Tyrosine hydroxylation

Indexed keywords

PHENYLALANINE; STABLE ISOTOPE; TYROSINE;

AMINO ACID METABOLISM; CATABOLISM; HUMAN; HYDROXYLATION; LIVER CIRRHOSIS; LIVER METABOLISM; METABOLIC REGULATION; PATHOPHYSIOLOGY; REVIEW;

HUMANS; HYDROXYLATION; KIDNEY; LIVER; LIVER CIRRHOSIS; PHENYLALANINE; TYROSINE;

EID: 73849109317     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0b013e32833383af     Document Type: Review

References (38)

1. Jungermann K, Katz N. Functional specialization of different hepatocyte populations. Physiol Rev 1989; 69:708-764.
2. Christensen HN. Inter-organ amino acid nutrition. Physiol Rev 1982; 62 (4 Pt 1):1193-1233.
3. Munro HN, Crim MC. The proteins and the amino acids. In: Shils ME, Young VR, editors. Aromatic amino acid account for about 6-8% of total amino acid residues in the proteins. Modern nutrition in health and disease., 7th ed. Philadelphia, USA: Lea & Febiger; 1988. pp. 1-37.
4. Tessari P, Kiwanuka E, Zanetti M, Barazzoni R. Postprandial body protein synthesis and amino acid catabolism measured with leucine and phenylala-nine-tyrosine tracers. Am J Physiol Endocrinol Metab 2003; 284:E1037-E1042.
5. Hufton SE, Jennings JG, Cotton RGH. Structure and function of the aromatic amino acid hydroxylases. Biochem J 1995; 311:353-366.
6. Lichter-Konecki U, Hipke CM, Konecki DS. Human phenylalanine hydroxylase gene expression in kidney and other nonhepatic tissues. Mol Genet Metab 1999; 67:308-316.
7. Tizianello A, De Ferrari G, Garibotto G, et al. Renal metabolism of amino acids and ammonia in subjects with normal renal function and in patients with chronic renal insufficiency. J Clin Invest 1980; 65:1162-1173.
8. van Spronsen FJ, Smit PG, Koch R. Phenylketonuria: tyrosine beyond the phenylalanine-restricted diet. J Inherit Metab Dis 2001; 24:1-4. (Pubitemid 32218834)
9. Fernstrom JD, Fernstrom MH. Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain. J Nutr 2007; 137 (6 Suppl 1):1539S-1547S; discussion 1548S.
10. Dejong CH, van de Poll MC, Soeters PB, et al. Aromatic amino acid metabolism during liver failure. J Nutr 2007; 137:1579S-1585S.
11. Morgan MY, Marshall AW, Milsom JP, Sherlock S. Plasma amino-acid patterns in liver disease. Gut 1982; 23:362-370.
12. McCullough AJ, Czaja AJ, Jones JD, Go VLW. The nature and prognostic significance of serial amino acid determinations in sever chronic active liver disease. Gastroenterology 1981; 81:645-652.
13. Canales JJ, Elayadi A, Errami M, et al. Chronic hyperammonemia alters motor and neurochemical responses to activation of group I metabotropic glutamate receptors in the nucleus accumbens in rats in vivo. Neurobiol Dis 2003; 14:380-390.
14. Scriver CR. The PAH gene, phenylketonuria, and a paradigm shift. Hum Mutat 2007; 28:831-845.
15. Carr FPA, Pogson CI. Phenylalanine metabolism in isolated liver cells. Biochem J 1981; 198:655-660.
16. Tourian A, Goddard J, Puck TT. Phenylalanine hydroxylase activity in mammalian cells. J Cell Physiol 1969; 73:159-170.
17. Shiman R, Gray DW. Substrate activation of phenylalanine hydroxylase. J Biol Chem 1980; 255:4793-4800.
18. 13C]phenylalanine. Am J Physiol 1990; 259:E835-E843.
19. 13C]tyrosine in the postabsorptive state. Metabolism 1982; 31:999-1005.
20. 5]phenylalanine model. Am J Physiol 1989; 256:E631-E639.
21. 13C]phenylalanine as tracers in man. Metabolism 1993; 42:1316-1322.
22. Reeds PJ, Hachey DL, Patterson BW, et al. VLDL apolipoprotein B-100, a potential indicator of the isotopic labeling of the hepatic protein synthetic precursor pool in humans: studies with multiple stable isotopically labeled amino acids. J Nutr 1992; 122:457-466.
23. Rafii M, McKenzie JM, Roberts SA, et al. The in vivo regulation of phenylalanine hydroxylation using enrichment in Apo-B 100. Am J Physiol 2008; 294: E475-F479.
24. Cortiella J, Marchini JS, Branch S, et al. Phenylalanine and tyrosine kinetics in relation to altered protein and phenylalanine and tyrosine intakes in healthy young men. Am J Clin Nutr 1992; 56:517-525.
25. Young VR, Marchini JS. Mechanisms and nutritional significance of metabolic responses to altered protein intakes of protein and amino acids, with reference to nutritional adaptation in humans. Am J Clin Nutr 1990; 51:270-289.
26. Barazzoni R, Zanetti M, Vettore M, Tessari P. Relationship between phenylalanine hydroxylation and plasma aromatic amino acid concentrations in humans. Metabolism 1998; 47:669-674.
27. House JD, Thorpe JM, Wykes LJ, et al. Evidence that phenylalanine hydroxylation rates are over-estimated in neonatal subjects receiving total parenteral nutrition with a high phenylalanine content. Pediatr Res 1998; 43:461-466.
28. Price GM, Halliday D, Pacy PJ, et al. Nitrogen homeostasis in man: influence of protein intake on the amplitude of diurnal cycling of body nitrogen. Clin Sci 1994; 86:91-102.
29. Tessari P, Deferrari G, Robaudo C, et al. Phenylalanine hydroxylation across the kidney in humans. Kidney Int 1999; 56:2168-2172.
30. Møller N, MeekS, Bigelow M, et al. The kidney is an important site for in vivo phenylalanine-to-tyrosine conversion in adult humans: a metabolic role of the kidney. Proc Natl Acad Sci USA 2000; 97:1242-1246.
31. Tessari P, Biolo G, Inchiostro S, et al. Leucine and phenylalanine kinetics in compensated liver cirrhosis. Gastroenterology 1993; 104:1712-1721.
32. Tessari P, Inchiostro S, Barazzoni R, et al. Fasting and postprandial phenylalanine and leucine kinetics in liver cirrhosis. Am J Physiol 1994; 267:E140-E149.
33. O'Keefe SJ, Abraham R, El-Zayadi A, et al. Increased plasma tyrosine concentrations in patients with cirrhosis and fulminant hepatic failure associated with increased plasma tyrosine flux and reduced hepatic oxidation capacity. Gastroenterology 1981; 81:1017-1024.
34. Hehir DJ, Jenkins RL, Bistrian BR, et al. Abnormal phenylalanine hydroxylation and tyrosine oxidation in a patient with acute fulminant liver disease with correction by liver transplantation. Gastroenterology 1985; 89:659-663.
35. 13C-tyrosine breath testsforthe measurement of hepatocyte functional capacity in patients with liver cirrhosis. Chem Pharm Bull 2001; 49:1507-1511.
36. Tessari P, Kiwanuka E, Vettore M, et al. Phenylalanine and tyrosine kinetics in compensated liver cirrhosis: effects of meal ingestion. Am J Physiol Gastro-intest Liver Physiol 2008; 295:G598-604.
37. Boirie Y, Albright R, Bigelow M, Nair KS. Impairment of phenylalanine conversion to tyrosine in end-stage renal disease causing tyrosine deficiency. Kidney Int 2004; 66:591-596.
38. Young GA, Parsons FM. Impairment of phenylalanine hydroxylation in chronic renal insufficiency. Clin Sci 1973; 45:89-97.